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Autophagy is a conserved catabolic process that
plays a housekeeping role in eliminating protein ag-
gregates and organelles and is activated during
nutrient deprivation to generate metabolites and
energy. Autophagy plays a significant role in tumori-
genesis, although opposing context-dependent
functions of autophagy in cancer have complicated
efforts to target autophagy for therapeutic purposes.
We demonstrate that autophagy inhibition reduces
tumor cell migration and invasion in vitro and attenu-
ates metastasis in vivo. Numerous abnormally large
focal adhesions (FAs) accumulate in autophagy-defi-
cient tumor cells, reflecting a role for autophagy in
FA disassembly through targeted degradation of
paxillin. We demonstrate that paxillin interacts with
processed LC3 through a conserved LIR motif in
the amino-terminal end of paxillin and that this inter-
action is regulated by oncogenic SRC activity.
Together, these data establish a function for auto-
phagy in FA turnover, tumor cell motility, and me-
tastasis.
INTRODUCTION
Macro-autophagy (hereinafter termed autophagy) is a catabolic
process important for the degradation of damaged organelles
and protein aggregates, as well as the intracellular recycling of
metabolites (Kroemer et al., 2010; Mizushima and Komatsu,
2011) that are used by tumor cells to survive nutrient stress, hyp-
oxia, and cytotoxic therapies (Amaravadi et al., 2011; Kimmel-
man, 2011; White, 2012). Consequently, autophagy has
emerged as a potential therapeutic target (Amaravadi et al.,
2011). However, such efforts are complicated by the growing1660 Cell Reports 15, 1660–1672, May 24, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://realization that autophagy plays opposing roles in tumorigen-
esis, likely influenced by the stage of progression, driving onco-
gene and tissue type (Galluzzi et al., 2015). Mouse models
support a tumor-suppressive role for autophagy in the early
stages of tumorigenesis by promoting genome stability and
limiting necrosis and inflammation (Degenhardt et al., 2006; Kar-
antza-Wadsworth et al., 2007; Mathew et al., 2009). Conversely,
autophagy is required for malignant progression (Guo et al.,
2013; Karsli-Uzunbas et al., 2014; Rao et al., 2014; Rosenfeldt
et al., 2013; Strohecker et al., 2013). Consistently, clinical studies
have associated increased staining for the autophagy marker
LC3 with melanoma metastases and with node positivity and
decreased overall survival in human breast cancer (Lazova
et al., 2012), whereas overexpression of the key autophagy regu-
lator Beclin1 is linked to reduced latency of melanoma metas-
tasis (Giatromanolaki et al., 2011).
Here, we report that autophagy is required for the motility and
invasion of highly metastatic tumor cells due to a function for
autophagy in promoting focal adhesion (FA) turnover. The key
FA protein paxillin is degraded by autophagy, and paxillin is
targeted to the autophagosome through the Src-regulated inter-
action of LC3 with a conserved LC3-interacting region (LIR) in
paxillin. These results broaden our understanding of the multi-
faceted role of autophagy in tumor progression and indicate
that inhibiting autophagy may be an effective approach to block-
ing metastatic dissemination in the clinic.
RESULTS
Knockdown of Atg5 or Atg7 in Metastatic Mammary
Tumor Cells Inhibits Autophagy without Inhibiting Cell
Growth
To explore the role of autophagy in metastasis, we used the 4T1
orthotopic mouse mammary tumor model, in which 4T1 murine
mammary carcinoma cells implanted into the mammary fat
pads of syngeneic BALB/c mice form primary tumors that spon-
taneously metastasize to the lung and liver (Aslakson and Miller,)
creativecommons.org/licenses/by-nc-nd/4.0/).
1992). We inhibited autophagy in 4T1 cells through stable, short-
hairpin (sh)-RNA (shRNA)-mediated knockdown of either Atg5 or
Atg7, two autophagy-regulatory proteins required for autopha-
gosome formation, in accordance with published guidelines
(Staskiewicz et al., 2013).
4T1 clones stably expressing shAtg5 exhibited no detectable
Atg5 protein in the presence or absence of the autophagy inhib-
itor bafilomycin A1 (bafA1) (Figure 1A). As expected, knockdown
of Atg5 also resulted in the absence of the Atg5-12 conjugate
(Figure S1A). Although parental cells exhibited robust autopha-
gic flux with bafA1 treatment, as measured by increased auto-
phagosome marker LC3B-II, shAtg5 clones failed to do so either
in the presence of bafA1 (Figures 1C and 1D) or under hypoxia
(Figure S1B). Similar results were obtained upon Atg7 knock-
down (Figures 1B, 1C, and 1E). Immunofluorescence (IF) for
endogenous LC3B revealed numerous punctae in parental and
control cells but only diffuse cytoplasmic staining in auto-
phagy-deficient cells (Figure 1F), demonstrating the lack of auto-
phagosome formation. Finally, electron microscopy revealed
abundant autophagosome/autolysosome structures in control,
but not shAtg5, cells (Figure 1G, red arrows).
Despite this marked inhibition of autophagy in Atg5- and Atg7-
deficient 4T1 cells, there was no significant decrease in cell
growth (Figures 1H and 1I) or viability, compared with parental
and scrambled shRNA cells, even when deprived of glucose or
oxygen (Figure 1J). Thus, although metastatic 4T1 tumor cells
exhibit high levels of autophagic flux, inhibition of autophagy
did not limit cell growth in vitro.
Autophagy Is Required for Metastasis of Tumor Cells
from the Mammary Gland to the Lung and Liver
Injection of engineered 4T1 tumor cells into the mammary fat
pads of syngeneic BALB/c female mice produced palpable
mammary tumors within 2 weeks and large tumors within
4 weeks. LC3B-positive puncta/autophagosomes were readily
visible in control tumors at 3 weeks but were absent in Atg5-
and Atg7-deficient tumors (Figure 2A), indicating that auto-
phagy was inhibited. However, consistent with in vitro data
(Figure 1I), autophagy-deficient tumors did not exhibit reduced
growth in vivo (Figure 2B), and there was no significant differ-
ence in the Ki-67 index (Figure 2C) or TUNEL staining (Fig-
ure 2D) between the autophagy-deficient and control tumors.
Taken together, these data indicate that 4T1 tumor cells do
not depend on autophagy for tumor cell proliferation or survival
in vivo.
Although primary tumor growth was unaffected, inhibition of
autophagy markedly reduced lung and liver metastases (Figures
2E and 2F). Numerous macro-metastases were evident in lung
and liver sections frommice with parental and scrambled control
tumors but notmicewith autophagy-deficient tumors (Figure 2E).
Quantification of lung metastases demonstrated a statistically
significant reduction (p < 0.0001) in mice bearing autophagy-
deficient tumors relative to parental or control tumors (Figure 2E).
To confirm these effects pharmacologically, mice with parental
tumors were treated with hydroxychloroquine (HCQ), an Food
and Drug Administration (FDA)-approved inhibitor of autophagy
with the same mechanism of action as bafA1 (Klionsky et al.,
2016). As with genetic inhibition of autophagy, HCQ treatmentdid not alter primary tumor growth (Figure S2A) but significantly
reduced lung metastasis (p < 0.0001) (Figure 2G). Together,
these results demonstrate that autophagy is required for sponta-
neous metastasis in the 4T1 in vivo model.
The known functions of autophagy in promoting cell survival
during extracellular matrix (ECM) detachment, growth factor
withdrawal, and nutrient deprivation (Fung et al., 2008; Kuma
et al., 2004) are believed to promote progression following
escape from the primary tumor. Indeed, autophagy is required
for tumor cell survival in the bloodstream during hepatocellular
carcinomametastasis (Peng et al., 2013). To investigate whether
autophagy is required at later stages of metastasis in the 4T1
model, engineered tumor cells were injected directly into the
circulation via the tail vein, bypassing earlier steps in the meta-
static cascade. After 2 weeks, autophagy-deficient tumor cells
formed as many lung metastases as parental and control cells
(Figures S2B and S2C), indicating that autophagy is not required
in thismodel for tumor cell survival in the circulation ormetastatic
outgrowth at secondary sites. This is consistent with our finding
that autophagy is not required for 4T1 tumor cell proliferation or
survival in vitro (Figures 1G and 1H), or for primary tumors in vivo
(Figures 2B–2D), and indicates that reduced metastasis of auto-
phagy-deficient tumors (Figures 2E and 2F) was due to failure to
escape from the primary tumor.
Autophagy Is Required for Tumor Cell Motility In Vitro
Consistent with the observed defect in spontaneous metastasis
in vivo, autophagy-deficient 4T1 cells exhibited markedly
decreased migration and invasion through collagen compared
with control cells (Figures 3A and 3B). Inhibition of autophagy
with chloroquine (CQ) also inhibited the motility of 4T1 cells (Fig-
ure 3C). Inhibition of autophagy in the metastatic MDA-MB-231
human breast cancer (Figures S3A–S3C) and B16.F10 mouse
melanoma (Figures S3D and S3E) cell lines produced similar ef-
fects. Furthermore, autophagy-deficient 4T1 cells exhibited
markedly altered morphology in time-lapse differential interfer-
ence contrast (DIC) imaging (Movies S1, S2, and S3). Unlike con-
trol cells, autophagy-deficient cells did not spread out (Figure 3D)
or form protrusions (Figure 3E). Together, these results indicate
that autophagy is required for metastatic tumor cell migration, in-
vasion, and spreading in vitro.
Given the change in the morphology of the autophagy-defi-
cient cells, which could be consistent with a transition to a
more epithelial cellular program, as well as recent work sug-
gesting that the autophagy adaptor protein p62/Sqstm1 regu-
lates Twist degradation (Qiang et al., 2014), we assessed Twist
and E-cadherin protein levels in autophagy-deficient cells but
found no difference relative to autophagy-competent cells (Fig-
ure S3F). Furthermore, because cell motility is driven by ATP,
the production of which can be supported by autophagy, we
also examined whether the motility defects of autophagy-defi-
cient cells were due to insufficient ATP levels. As expected,
Atg5 knockdown reduced cellular ATP levels. However,
although treatment with methyl pyruvate restored ATP levels
(Figure S3G), it failed to rescue cell invasion (Figure S3H) or
protrusion formation (Figure S3I). Thus, the defective motility
of autophagy-deficient tumor cells was not due to reduced
ATP levels.Cell Reports 15, 1660–1672, May 24, 2016 1661
Figure 1. Autophagy-Deficient 4T1 Cells Do Not Exhibit Altered Growth Rate
(A) Western blot for Atg5 in parental, scrambled shRNA and two Atg5 shRNA-expressing 4T1 clones in the presence or absence of 100 nM bafA1 (4 hr).
(B) Detection of Atg7 by IP followed by western blotting in parental, control, and Atg7 shRNA cells. IB, immunoblot.
(C) Densitometric quantification of LC3B-II in parental and scrambled Atg5 and Atg7 shRNA cells ± bafA1 (***p < 0.001; NS, not significant). Data indicate mean ±
SEM; n = 3.
(D and E) Representative western blot for LC3B-I and II in Atg5- and Atg7-deficient cells ± bafA1.
(F) IF for endogenous LC3.
(G) Electron microscopy of autophagy-competent (left) and -deficient (right) 4T1 cells.
(H and I) Cell growth in complete medium over 96 hr. Data indicate mean ± SEM; n = 3.
(J) Cell viability after 24 hr in completemedium lacking glucose or at 1%O2 assessed by propidium iodide (PI) exclusion. Data indicatemean ±SEM; n = 2. NS, not
significant.
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Figure 2. Autophagy Inhibition Reduces
Metastasis to the Lung and Liver
(A) Immunohistochemistry for LC3B in control (i),
Atg5-deficient (ii), and Atg7-deficient (iii) 4T1 pri-
mary tumors at 3 weeks. Scr, scrambled.
(B) Orthotopic tumor volume of parental and
scrambled Atg5, and Atg7 shRNA tumors over
time (p = 0.2106, repeated-measures ANOVA).
Data indicate mean ± SEM; n = 8.
(C and D) Quantification of nuclear proliferation
marker Ki-67 (C) and TUNEL staining (D) of tumors
after 4 weeks. Data indicate mean ± SEM, n = 6.
NS, not significant.
(E) Representative H&E-stained sections of lungs
and livers of mice with parental and scrambled
Atg5 and Atg7 shRNA tumors 4 weeks post-or-
thotopic injection.
(F) Mean number of lung metastases in mice with
control or autophagy-deficient tumors at 4 weeks
(p < 0.0001, one-way ANOVA). Data indicate
mean ± SEM; n = 15 (parental), n = 20 (scrambled
shRNA), n = 18 (Atg5 shRNA-1 and -2), and n = 8
Atg7 (shRNA-1 and -2). NS, not significant.
(G) Mean number of lung metastases at 4 weeks in
mice with parental tumors that received PBS or
60 mg/kg HCQ i.p. every 3 days following tumor
implantation (p < 0.0001, one-way ANOVA). Data
indicate mean ± SEM; n = 8 per group.
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Figure 3. Autophagy Is Required for Escape from the Primary Tumor In Vivo and Cell Migration In Vitro
(A and B) Quantification of migration and invasion through collagen for parental, scrambled (Scr) shRNA and Atg5-deficient (A) and Atg7-deficient (B) 4T1 clones
(**p < 0.01; ***p < 0.001; ****p < 0.0001, one-way ANOVA; NS, not significant). Data indicate mean ± SEM; n = 3.
(C) Invasion and migration of parental 4T1 cells ± 50 mM CQ (*p < 0.05; ***p < 0.001). Data indicate mean ± SEM; n = 3.
(D) Depth heatmap of cell spreading of scrambled and Atg5-deficient 4T1 cells.
(E) Representative DIC images of control and autophagy-deficient 4T1 cells with altered cell morphology. Scale bars represent 10 mm.FA Disassembly Is Impaired in Autophagy-Deficient
Tumor Cells
FAs are largemacromolecular complexes that link the actin cyto-
skeleton to the ECM to provide traction, and properly regulated
FA dynamics are critical for cell migration (Parsons et al., 2010;
Ridley, 2011; Webb et al., 2002). IF for the FA proteins paxillin
and zyxin revealed an increase in both FA size and number in
autophagy-deficient cells (Figures 4A–4C). Although paxillin is
recruited early to nascent FAs (Laukaitis et al., 2001), zyxin is
found only in mature FAs (Zaidel-Bar et al., 2003), indicating
that the more numerous and larger FAs in the autophagy-defi-
cient cells were mature. This phenomenon was replicated
upon bafA1 treatment of both parental 4T1 and B16.F10 cells
(Figures S4B and S4C). As with the morphologic changes
(Figure 3E), the alteration in FAs was density independent (Fig-
ure 4A; Figure S4A). The FA abnormalities were observed in
autophagy-deficient cells grown on glass, fibronectin, or
collagen I (Figure S4D), indicating that defects in cell spreading
and FA accumulation were not due to altered interaction with
or modulation by the cellular substratum.
To determine whether the FA abnormalities in autophagy-defi-
cient tumor cells were the result of altered FA dynamics, we
assessed FA assembly and disassembly rates using time-lapse
imaging of EGFP-paxillin FAs in control and Atg5-deficient 4T1
cells (Figure 4D; Movies S4 and S5). EGFP-paxillin incorporation1664 Cell Reports 15, 1660–1672, May 24, 2016into, and disappearance from, FAs was linear on a semiloga-
rithmic plot of fluorescence intensity over time, as described
previously (Webb et al., 2004), allowing us to calculate assembly
and disassembly rate constants (Figure 4E). Although Atg5-defi-
cient cells exhibited no difference in FA assembly rates relative to
control cells, the disassembly rate was significantly reduced;
FAs disassembled completely within 15 min in control cells
(Figure 4D, top panel, arrows) but requiredR30min in Atg5-defi-
cient cells (Figure 4E, bottom panel, arrows). Therefore, inhibi-
tion of autophagy increases FA size and number due to impaired
FA disassembly.
Aberrant FAs in Autophagy-Deficient Tumor Cells Are
Associated with Paxillin Accumulation
Cells lacking FAK (Ilic et al., 1995), catalytically active Src (Fin-
cham and Frame, 1998), or paxillin (Hagel et al., 2002) exhibit
decreased spreading and migration associated with increased
FA number and size and exhibit impaired FA disassembly
(Webb et al., 2004), similar to our observations in autophagy-
deficient 4T1s. Although we did not detect any changes in FAK
or Src protein levels or phosphorylation (Figures S5A and S5B),
we observed a marked increase in total paxillin protein levels in
autophagy-deficient 4T1 cells (Figures 5A and 5B). BafA1
increased paxillin protein levels in parental, but not autophagy-
deficient, 4T1 cells (Figures 5A–5C) as well as in MDA-MB-231
Figure 4. Autophagy-Deficient 4T1 Cells
Have Defective FA Disassembly
(A) IF of FA proteins paxillin and zyxin in control and
autophagy-deficient cells. Scale bars represent
20 mm.
(B and C) Quantification of FAs per nucleus (B) and
average FA size (C) per 633 field (**p < 0.01; ****p <
0.0001, one-way ANOVA; NS, not significant).
Data indicate mean ± SEM; n = 10. Scr, scra-
mbled.
(D) Time-lapse TIRF imaging of EGFP-paxillin FAs
in control and Atg5-deficient cells. Inset: repre-
sentative disassembly of adhesions (arrows) over
15 min (control) or 30 min (Atg5 deficient).
(E) Rate constant for increase in EGFP-paxillin
fluorescence during FA formation (mean ± SEM,
n = 11) and for decrease in EGFP-paxillin fluores-
cence during FA turnover (****p < 0.0001; NS, not
significant). Data indicate mean ± SEM; n = 13
(scrambled shRNA), and n = 15 (Atg5 shRNA).and B16.F10 cells (Figures 5D and 5E). Paxillin levels were also
elevated in lysates from Atg5- and Atg7-deficient tumors relative
to control primary 4T1 tumors (Figure 5F). Immunohisto-
chemistry confirmed these increased paxillin levels in auto-
phagy-deficient tumors (Figure 5G). Thus, autophagy inhibition
is associated with paxillin accumulation in vitro and in vivo.
To determine whether increased paxillin levels underlie the cell
motility and FA defects in autophagy-deficient 4T1s, we used
small interfering RNA (siRNA) to knock down paxillin expression
in autophagy-deficient 4T1 cells to levels similar to those in
parental cells (Figure 5H). Reducing paxillin levels in auto-
phagy-deficient cells normalized FA morphology (Figure 5I).
Importantly, knockdown of paxillin and normalization of FAsCell Rrescued the motility of autophagy-defi-
cient cells (Figures 5J and 5K). Together,
these results demonstrate that inhibition
of autophagy in metastatic tumor cells
results in the accumulation of paxillin,
thereby inhibiting FA disassembly, cell
spreading, and cell motility.
Paxillin Is Stabilized in Autophagy-
Deficient Cells and Colocalizes
with LC3
Increased paxillin in autophagy-deficient
cells was not due to increased paxillin
mRNA levels (Figure S5C) but was asso-
ciated with increased protein stability
(Figure S5D), indicating that inhibition of
autophagy reduces paxillin degradation.
Paxillin can be degraded at the protea-
some (Abou Zeid et al., 2006), and auto-
phagy inhibition can reduce proteasomal
activity (Korolchuk et al., 2009). However,
proteasomal inhibition with MG132 or
ALLN did not increase paxillin levels in
control 4T1 cells (Figure S5E), and pro-teasomal degradation was not inhibited in autophagy-deficient
4T1 cells (Figure S5F). Thus, we investigated a direct role for
autophagy in degrading paxillin.
By live-cell confocal imaging, we detected mApple-paxillin in
punctate cytosolic structures that co-localized with the auto-
phagosome marker EGFP-LC3B (Figure 6A; Figure S6A),
confirming that paxillin colocalizes with autophagosomes in
autophagy-competent 4T1 cells. EGFP-LC3B also co-localized
with mApple-paxillin-positive FA structures (Figure 6B; Fig-
ure S6A), indicating that autophagosomes co-localize with FAs
in parental cells, consistent with previous reports (Sandilands
et al., 2012). In combination with our data demonstrating
that both transient and permanent inhibition of autophagic fluxeports 15, 1660–1672, May 24, 2016 1665
Figure 5. Autophagy-Deficient 4T1 Cells
Have Increased Paxillin
(A and B) Western blot for paxillin in control and
autophagy-deficient 4T1 cells ± 100 nM bafA1
(4 hr) to inhibit autolysosomal degradation.
(C) Densitometric quantification of paxillin fold in-
crease with bafA1 in parental and scrambled,
Atg5, and Atg7 shRNA 4T1 cells (**p < 0.01; ***p <
0.001; NS, not significant). Data indicate mean ±
SEM; n = 3.
(D and E) Western blot for paxillin ± bafA1 (4 hr) in
MDA-MB-231 (D) and B16.F10 (E) cells.
(F) Western blot for paxillin in lysates from parental
and scrambled Atg5 and Atg7 shRNA-expressing
4T1 primary tumors 3 weeks after orthotopic in-
jection.
(G) Paxillin immunohistochemistry in parental and
scrambled Atg5 and Atg7 shRNA-expressing 4T1
primary tumor sections 3 weeks after orthotopic
injection. Scale bars, 50 mm.
(H) Western blot confirming paxillin knockdown in
autophagy-deficient 4T1 cells.
(I) Paxillin and zyxin IF in autophagy-deficient 4T1
cells treated with control or paxillin siRNA.
(J and K) Quantification of the effect of siRNA-
mediated paxillin knockdown in autophagy-defi-
cient 4T1 cells on migration and invasion (**p <
0.01). Data indicate mean ± SEM; n = 3.increase paxillin levels, the colocalization of paxillin with
autophagosomes strongly suggests that paxillin is degraded
by autophagy. Immunohistochemistry revealed punctate paxillin
staining in 4T1 tumors expressing scrambled, but not Atg5,
shRNA (Figure S6B), consistent with the presence of paxillin at
autophagosomes in vivo.
Paxillin Interacts Directly with LC3
Paxillin can be ubiquitinated (Didier et al., 2003), and cargo re-
ceptor proteins such as p62/Sqstm1 and Nbr1 are known to
target ubiquitinated proteins to autophagosomes for degrada-1666 Cell Reports 15, 1660–1672, May 24, 2016tion (Rogov et al., 2014); both have been
implicated in the regulation of cell migra-
tion (Kenific et al., 2016; Qiang et al.,
2014), However, neither paxillin accumu-
lation (Figures S6C and S6D) nor reduced
cell migration or invasion (Figures S6E
and S6F) were observed in 4T1 cells
knocked down for p62/Sqstm1 or Nbr1,
indicating that neither protein is involved
in paxillin degradation. Cytosolic proteins
and macromolecular structures can also
be targeted for autophagy via direct inter-
action with processed LC3 (Rogov et al.,
2014). We identified a LIR motif, defined
by the presence of the conserved
sequence [W/F/Y]-xx-[L/I/V] (Birgisdottir
et al., 2013) in paxillin at amino acids
40–43 (Figure 6C). The putative paxillin
LIR resembles that of Nbr1, with the aro-matic residue Y40 in position +1 and the hydrophobic residue
I43 in position +4. The acidic residue in the +2 position and thre-
onine in the 1 position have also been shown to contribute to
interactions of validated LC3-interacting proteins with LC3 (Bir-
gisdottir et al., 2013). Furthermore, the putative LIR in paxillin is
highly conserved from Xenopus through humans (Figure S6G).
Given that paxillin colocalizes with LC3B in the cytosol and at
FAs (Figures 6A and 6B), we tested for an interaction between
LC3B and paxillin. We successfully co-immunoprecipitated
mApple-paxillin and trace levels of endogenous paxillin
with EGFP-LC3B in both 4T1 (Figure 6D) and B16.F10 cells
Figure 6. Paxillin Co-localizes with Autophagosomes
(A and B) 4T1 cells expressing mApple-paxillin and EGFP-LC3B were treated with bafA1, and live cells were imaged by confocal microscopy. 3D reconstruction
reveals that mApple-paxillin colocalizes with EGFP-LC3B (arrows) (A) and that EGFP-LC3B colocalizes with FAs (arrows) (B).
(C) Alignment of human paxillin residues 37–43 (bottom) with the 3 to +4 residues of known tryptophan- and tyrosine-containing LIRs.
(legend continued on next page)
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(Figure 6E). Furthermore, an in vitro binding assay demonstrated
that paxillin was pulled down with GST (glutathione S-trans-
ferase)-LC3B, but not GST, demonstrating that LC3B is able to
directly bind paxillin in the absence of any adaptors (Figure S6H).
Consistent with these results, shRNA-mediated knockdown of
LC3B (Figure S6I) led to an accumulation of paxillin (Figure 6F),
enlarged FAs (Figure 6G), and reduced cell motility (Figures 6H
and 6I), phenocopying the effects of Atg5 and Atg7 deficiency.
These data illustrate the requirement for a direct interaction be-
tween paxillin and LC3B-II to promote targeted degradation of
paxillin by autophagy and FA disassembly.
Defining a LIR Motif in Paxillin that Is Regulated by Src
To determine whether the interaction of paxillin with LC3 re-
quires the putative LIR motif, we generated a paxillin mutant
in which the critical tyrosine at the +1 position of the putative
LIR was mutated to alanine (Y40A), as well as a mutant in which
positions +2 through +4 were mutated to alanine (QEIAAA). The
Y40A and QEIAAA mutants localized properly to FAs (Fig-
ure S7E), but both mutations significantly reduced the colocal-
ization of mApple-paxillin with EGFP-LC3 (Figures 7A–7C) in
4T1 cells stably depleted of endogenous paxillin (Figure S7A).
These mutations also abrogated the co-immunoprecipitation
(coIP) of mApple-paxillin with EGFP-LC3 (Figure 7D, lane 3
and lane 8), although the Y40A mutation exhibited a greater
inhibitory effect on the paxillin-LC3 interaction than the QEIAAA
mutation. Furthermore, cells expressing the mApple-paxillin
mutants exhibited reduced motility relative to cells expressing
wild-type (WT) mApple-paxillin (mApple-paxillin-WT) (Fig-
ure S7B). These results validate the LIR motif in paxillin and
highlight the key function of the Y40 residue in the interaction
of paxillin with LC3.
A tyrosine at position +1 is less commonly found in LIR motifs
than the canonical +1 tryptophan (Figure 6C) (Birgisdottir et al.,
2013). Intriguingly, the Y40 residue of paxillin is a known phos-
phorylation target of Src tyrosine kinase, although its functional
significance is not well established (Schaller and Schaefer,
2001; Webb et al., 2005). CoIP of mApple-paxillin with EGFP-
LC3 was strongly stimulated by constitutively active SrcY527F in
both paxillin knockdown 4T1 cells (Figure 7D, lanes 2 and 4)
and B16.F10 cells (Figure S7C). Significantly, the Y40A mutation
blocked the effect of SrcY527F (Figure 7D, lane 5), while the
QEIAAA mutation significantly blunted it (Figure 7D, lane 10), indi-
cating that Src modulates the interaction of paxillin with LC3 via
the identified LIR motif. Interestingly, the Y31 and Y118 residues
in paxillin, which are the sites classically regulated by Src phos-
phorylation (Deakin and Turner, 2008), were not required for
either the basal interaction of paxillin with LC3 or the response
to Src (Figure S7C). Taken together, these results indicate that
the LIR motif of paxillin, and the Y40 residue in particular, is
critical to the interaction of paxillin with LC3B and that this inter-
action is regulated by oncogenic Src.(D and E) CoIP of mApple-paxillin and endogenous paxillin with GFP-LC3 in pare
(F) Western blot for paxillin in control and LC3B-deficient 4T1 cells ± 100 nM baf
(G) IF of FA proteins paxillin and zyxin in control and LC3B-deficient cells.
(H and I) Quantification of invasion (H) and migration (I) of autophagy-deficient 4T1
significant). Data indicate mean ± SEM; n = 3.
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Src-Stimulated Motility
To determine whether the Src-regulated interaction of paxillin
and LC3 underlies the motility defects of autophagy-deficient
cells, we performed transwell migration assays. Although the
expression of SrcY527 strongly stimulated the motility of control
4T1 cells, it failed to do so in autophagy-deficient shAtg5
cells (Figure 7E). Furthermore, the motility of cells expressing
mApple-paxillin-WT was strongly stimulated by the co-expres-
sion of SrcY527F (Figure 7E), but cells expressing either the
Y40A or QEIAAA mutants were defective for Src-stimulated
motility (Figure 7F). These data demonstrate that stimulation of
the interaction between paxillin and LC3 by oncogenic Src and
the subsequent autophagic degradation of paxillin promote
cellular migration.
In summary, our work identifies a role for autophagy in promot-
ing metastatic tumor cell migration and invasion by degrading
paxillin and promoting FA disassembly that is dependent on
the Src-regulated interaction of paxillin with processed LC3B.
DISCUSSION
We have demonstrated that autophagy promotes cell spreading,
migration, and invasion of highly metastatic tumor cells in vitro
and is required for early steps in the metastatic cascade in the
4T1 mouse mammary tumor model in vivo, with similar effects
observed in the MDA-MB-231 human breast cancer and
B16.F10 melanoma cell lines. Our data establish that autophagy
is required to promote FA disassembly by degrading the FA pro-
tein paxillin, that paxillin interacts directly with LC3B, and that the
conserved amino-terminal LIR motif is critical to the interaction.
Consistent with the knowledge that Y40 in the paxillin LIRmotif is
an established Src phosphorylation target, expression of consti-
tutively active SrcY527F dramatically increased both the interac-
tion of paxillin with LC3B and tumor cell motility. Furthermore,
Atg5-deficient cells were refractory to the migration-stimulatory
effects of SrcY527F, indicating that autophagy plays a critical role
downstream of oncogenic Src in promoting FA disassembly
through targeted degradation of paxillin. Interestingly, Src phos-
phorylation of a critical tyrosine in the LIR motif of FUNDC1 has
been reported to modulate the interaction of this protein also
with LC3B (Liu et al., 2012).
Likely due to the aggressive nature of the metastatic tumor
cells examined here, we did not observe significant reductions
in cell growth or viability in vitro (Figures 1I and 1J) or in vivo (Fig-
ure 2B) following autophagy inhibition. Importantly, although
autophagy-deficient 4T1 cells were unable to metastasize
successfully from an orthotopic site, they were able to colonize
the lung when injected directly into the circulation, indicating
that survival in the circulation and outgrowth in the lung were
not impaired by loss of autophagy in this model. Thus, we have
been able to separate a specific requirement for autophagy inntal 4T1 (D) and B16.F10 cells (E).
A1 (4 hr).
cells relative to parental and scrambled cells (**p < 0.01; ***p < 0.001; NS, not
Figure 7. The LIR Motif of Paxillin Is Critical
for Interaction with LC3 and Is SRC Regu-
lated
(A–C) Images (A) and quantification (B and C) of
shPaxillin 4T1 cells co-expressing EGFP-LC3B
and mApple-paxillin-WT, Y40A, or QEIAAA. Per-
centage of cells with colocalization (**p < 0.01).
Data indicate mean ± SEM; n = 2, 15–20 cells per
condition per experiment. Colocalization events
per cell (***p < 0.001). Data indicate mean ± SEM;
n = 30.
(D) CoIP of mApple-paxillin-WT and Y40A or
QEIAAA with GFP-LC3 in shPaxillin 4T1 cells in the
presence or absence of active SrcY527F.
(E) Quantification of migration and invasion of
scrambled (Scr) shRNA and shAtg5 cells in the
presence or absence of SrcY527F (**p < 0.01; ***p <
0.001). Data indicate mean ± SEM; n = 4. NS, not
significant.
(F) Quantification of the SrcY527F-simulated fold
change in the migration and invasion of cells ex-
pressing mApple-paxillin-WT, Y40A, or QEIAAA
(*p < 0.05; **p < 0.01; ****p < 0.0001). Data indicate
mean ± SEM; n = 6.cell motility during metastasis that is independent of effects on
proliferation or cell viability.
The link between autophagy and paxillin was first suggested
based on genetic interactions between Atg1 and paxillin in
D. melanogaster (Chen et al., 2008). However, the degradation
of paxillin is not the only mechanism by which autophagy can
modulate FA dynamics. Treatment of patient-derived glioblas-
toma cells with phosphatidylinositol 3-kinase, an upstream
regulator of autophagy, increased tumor cell motility through
mitochondrial redistribution to the cortical cytoskeleton to
promote FA turnover (Caino et al., 2015). Additionally, FIP200,
a protein that forms part of the Ulk1/Atg13 pre-initiation complexCell R(Hara et al., 2008), inhibits FAK autophos-
phorylation and cellular migration when
overexpressed (Abbi et al., 2002). Finally,
AMPK activation induces autophagy but
reduces cell migration in an Ulk1- and
FIP200-dependent manner in glioblas-
toma, prostate cancer cells, and normal
fibroblasts (Caino et al., 2013). We did
not observe any change in FAK autophos-
phorylation (Figure S5A) or FIP200 levels
(data not shown) when autophagy was in-
hibited, but it is possible that alterations in
autophagic flux could alter FIP200-FAK
signaling in other systems not studied
here.
Our work adds to a growing body of
work linking autophagy to tumor cell
motility, invasion, and metastasis (Kenific
et al., 2016; Lock et al., 2014; Macintosh
et al., 2012; Qiang et al., 2014). A recent
study identified a critical role for auto-
phagy in the secretion of matrix metallo-proteinases (MMPs) and cytokines during RAS-driven invasion
(Lock et al., 2014), and knockdown of Atg12 has been shown
to inhibit invasion in a glioblastoma cell line (Macintosh et al.,
2012). Overexpression of autophagy genes has been associated
with the more aggressive mesenchymal subtype of primary
glioblastoma, and the substrate adaptor p62/Sqstm1 and auto-
phagic flux were required for the invasion and migration of
glioblastoma stem-like cell lines (Galavotti et al., 2013). However,
an autophagy-independent role for p62 in promoting cell mi-
gration by binding Twist and preventing its degradation has
also been identified (Qiang et al., 2014). We observed that
paxillin turnover by autophagy was independent of p62/Sqstm1eports 15, 1660–1672, May 24, 2016 1669
(Figure S6C), indicating that autophagy canmodulate cellular dy-
namics through both p62-independent and p62-dependent
mechanisms. We also show that, in the highly metastatic tumor
cells examined here, NBR1, a different cargo receptor protein
implicated in themigration of Ras-expressing epithelial cells (Ke-
nific et al., 2016), does not stabilize paxillin (Figure S6D). How-
ever, we cannot rule out the possibility that adaptors other
than p62/Sqstm1 and NBR1 may facilitate binding of paxillin to
LC3B. Finally, the levels of Twist and E-cadherin were un-
changed in autophagy-deficient 4T1 cells (Figure S3F), indi-
cating that the motility defects of autophagy-deficient tumor
cells here were not explained by the mechanisms reported in
other studies (Kenific et al., 2016; Qiang et al., 2014). This sug-
gests that autophagy regulates cell motility through different
mechanisms in different cell types and that the mechanism
described here may be specific to highly metastatic and mesen-
chymal tumor cells. Finally, the requirement for autophagy in the
survival of dormant tumor cells in GIST (Gupta et al., 2010) and
ovarian cancer (Lu et al., 2008) illustrates an additional role for
autophagy at a later step in the metastatic cascade. Together
with our work identifying a critical role for autophagy in FA disas-
sembly through paxillin degradation and its requirement for
escape from the primary tumor, these studies highlight the po-
tential utility of inhibiting autophagy to block tumor metastasis.
EXPERIMENTAL PROCEDURES
Cell Culture
Cells were grown in DMEM/10% FBS/1% penicillin and streptomycin (Pen/
Strep) (1% MEM-NEAA was added to 4T1 media). Mouse Atg7
(TRCN0000375444), p62 (TRCN0000098619), Nbr1 (TRCN0000238310),
MAP1LC3B/Atg8 (TRCN0000120800), paxillin (TRCN0000305025), and
non-targeting control shRNA (SHC002) and custom shRNA to human/mouse
ATG5/Atg5 (GCATTATCCAATTGGTTT seed sequence) were from Sigma.
Non-targeting control (Santa Cruz Biotechnology, sc-37007) and paxillin
siRNA (Santa Cruz, sc-36197) were used at 50 nM. ATP was measured with
the ATP Bioluminescence Assay Kit CLS II (Roche).
Chemicals
BafA1 and MG132 were from Enzo Life Sciences. Chloroquine, ALLN, and
human plasma fibronectin were from Sigma; methyl pyruvate was from Fluka;
and rat tail collagen I and Matrigel were from BD Biosciences.
Transwell Assays
For migration assays, 5 3 104 (4T1), 4 3 104 (MDA-MB-231), or 9 3 104
(B16.F10) cells in serum-free medium were seeded per 8-mm-pore cell-culture
insert (BD Biosciences). Inserts were pre-coated with collagen I (BD Biosci-
ences; 4T1 and MDA-MB231) or Matrigel (BD Biosciences; B16.F10) for
invasion assays, and 1 3 105 (4T1), 9 3 104 (MDA-MB-231), or 1.5 3 105
(B16.F10) cells were seeded per insert. Complete medium was added outside
of the insert, and plates were incubated at 37C for 16 hr. Cells were fixed in
4% paraformaldehyde (PFA), Giemsa-stained, non-migrated cells were
scraped from the inner side of the insert, and migrated/invaded cells were
counted in five 203 fields per insert. Assays were performed in triplicate.
Mice and Tumor Studies
All animal experiments were performed in accordance with IACUC approved
protocol 71155 at the University of Chicago. For orthotopic injections, MAP-
tested 4T1 cells (104 cells in 100 ml per mouse) were injected into themammary
fat pads of 8-week-old female BALB/c mice (Charles River Laboratories).
Tumor volume (calculated as L 3 W2, where L = length and W = width) was
measured weekly with electronic calipers. HCQ (60 mg/kg) was delivered
intraperitoneally (i.p.) every 3 days following tumor implantation. Tumors,1670 Cell Reports 15, 1660–1672, May 24, 2016lungs, and livers were harvested at 4 weeks post-orthotopic injection, fixed
in 10% neutral buffered formalin (NBF), embedded in paraffin, sectioned,
and stained as described later. For tail vein injections, 5 3 105 cells in 100 ml
were injected per 8-week-old female BALB/c mouse (Charles River Labora-
tories), and lungs were harvested at 2 weeks and processed as described
earlier. ImageJ was used to segment and count lung metastases on eight
H&E-stained 25-mm serial lung sections per mouse for both spontaneous
and experimental metastasis assays.
Immunohistochemistry
Ki-67 quantification, TUNEL staining, and LC3B immunohistochemistry were
performed as described previously (Rosenfeldt et al., 2012). Paxillin was de-
tected in situ using a specific antibody (Santa Cruz, H-114, 1:80 dilution) and
standard immunohistochemistry. Stained sections were digitized and quanti-
fied using a ScanScope XT automated slide scanning system and Spectrum
Plus image analysis software (Aperio). For Ki-67, a tuned nuclear quantification
v9 algorithm was used to report DAB+ nuclei as a percentage of total (hema-
toxylin-stained) nuclei on ten random non-necrotic 0.25-mm2 sections per
slide. For TUNEL, a tuned color deconvolution v9 algorithm was used to report
DAB+ area as a percentage of total tissue area for each section.
Western Blots and IP Analyses
Primary antibodies were a-LC3, a-Atg5 (Novus); a-Atg7, a-b-actin (Sigma);
a-Atg12, a-Nbr1 (Cell Signaling); a-paxillin (clones 177 [western blot; WB]
and 349 [IF]), E-cadherin (BD Biosciences); Twist (Abcam); a-GFP (Santa
Cruz); and a-ubiquitin (Pierce). Cells were lysed in RIPA (1% sodium deoxy-
cholate, 0.1% SDS, 1% Triton X-100, 10 mM Tris-HCl [pH 8.0], 0.14 M NaCl)
or NP40 buffer (LC3 WBs; 150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 1 mM
EDTA, 1% NP40 buffer) with protease and phosphatase inhibitors. Lysates
were centrifuged at 16,3003 g for 15min at 4C; supernatants were separated
by SDS-PAGE. After transfer to nitrocellulose or polyvinylidene fluoride (PVDF)
(LC3), membraneswere blocked inmilk or BSA and incubated at 4Covernight
with primary antibody. Detection was performed by enhanced chemilumines-
cence after 2-hr incubation with horseradish-peroxidase (HRP)-conjugated
secondary antibodies (Dako).
For coIPs, cells were lysed in IP lysis buffer (150 mM NaCl, 50 mM Tris-HCl
[pH 8], 5 mM EDTA, 5% glycerol, 1% triton, 25 mM NaF) supplemented with
phosphatase and protease inhibitors (Roche). Lysates were pre-cleared 1 hr
with binding control agarose beads and incubated overnight with GFP-Trap
agarose beads (Chromtek) at 4C. Beads were washed in IP lysis buffer, and
bound protein was eluted.
For in vitro binding assays, GFP-Trap agarose beads (Chromtek) were incu-
bated with 5 mg GST (Novus) or GST-LC3B (Enzo) in IP lysis buffer for 1 hr at
4C, washed, and blocked with 5% BSA overnight. Subsequently, beads
were washed and incubated 1 hr with 0.5 mg paxillin (Origene) at 4C. After final
washes, bound protein was eluted. All densitometry was performed on
scanned films using ImageJ (NIH). Band intensities were normalized to the
loading control, and normalized values are reported as fold change relative
to the first lane.
IF
For LC3B staining, cells were fixed in 4% PFA, permeabilized in 100% MeOH
at 20C, and blocked in 2% fetal bovine serum (FBS)/1% goat serum/PBS.
Otherwise, cells were fixed and permeabilized (3.7% PFA/PBS in 100 mM
PIPES [pH 6.8], 10 mM EGTA, 1 mM MgCl2, and 0.2% Triton-X), washed in
Tris-buffered saline (TBS)/0.1% Triton-X, and blocked in TBS/0.1% BSA.
Primary antibodies were a-LC3 (Cell Signaling), a-Paxillin (BD Biosciences
clone 349), and a-Zyxin (B71, Mary Beckerle, University of Utah). Cells were
imaged with an Axiovert 200M wide-field fluorescence microscope (Zeiss).
Image deconvolution was performed with Openlab software (PerkinElmer);
all other image analysis was performed with ImageJ.
Quantification of FA Size and Number
After image deconvolution, an ImageJ macro was written to perform the
following steps: one round of background subtraction followed by threshold-
ing on FAs with the renyi entropy algorithm. The analyze-particles function
was used to measure the number of FAs and total FA area. To confirm that
this accurately represented the FAs in the original image, the particles
analyzed were manually compared to the original. For each experiment,
10–12 images/120–150 cells per sample were analyzed.
Live-Cell Microscopy and Quantification of FA Dynamics
Timelapse DIC was performed with an Olympus LCV110U VivaView micro-
scope system. 3D cell-depth imaging was performed using a Zeiss LSM780
microscope. Total internal reflection fluorescence (TIRF) imaging of EGFP-
paxillin FAs was performed with a Leica TIRFM superresolution microscope
system (evanescent wave depth, 80 nm; images acquired every 60 s for
30 min). No significant photobleaching occurred. The fluorescent intensity of
individual EGFP-paxillin FAs over time on background-subtracted images
was determined using ImageJ. Semilogarithmic plots of fluorescent intensity
as a function of time were linear for both assembly and disassembly of
EGFP-paxillin FAs, and rate constants were calculated from the slopes.
Average rate constants were determined from 10–15 FAs from five cells for
each sample. Confocal imaging of mApple-paxillin and EGFP-LC3B was
performed on an Olympus DSU Spinning Disk confocal microscope. Colocal-
ization was analyzed on background-subtracted Z-stacks (0.5-mm slices) in
ImageJ using the the JACoP object-based method (Bolte and Cordelie`res,
2006) with 10–15 images (10–25 cells) per condition per experiment.
Statistics
Datawere analyzed withGraphPad Prism. Significancewas determined by un-
paired Student’s t test for two-group comparisons and one-way ANOVA for
comparisons of more than two groups. A Tukey post hoc test was used to
identify significant pairwise differences when a one-way ANOVA identified a
significant difference between means. Significance for tumor growth curves
was determined by repeated-measures two-way ANOVA.
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